FSD Pharma Files Material Change Report Update
Ticker: QNTM · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, material-change-report, registration-statement
TL;DR
FSD Pharma updated its material change report on July 4th, filed July 8th. Check the F-3 for details.
AI Summary
FSD Pharma Inc. filed a Form 6-K on July 8, 2024, incorporating by reference an Amended and Restated Material Change Report dated July 4, 2024. This filing includes a press release related to the amended report, which is incorporated into the company's F-3 registration statement.
Why It Matters
This filing provides an update on material changes within FSD Pharma Inc., which could impact investors' understanding of the company's current status and strategic direction.
Risk Assessment
Risk Level: low — This filing is primarily an administrative update and incorporation by reference of previously disclosed information, not a new material event.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- July 8, 2024 (date) — Filing date of Form 6-K
- July 4, 2024 (date) — Date of Amended and Restated Material Change Report
- Form F-3 (document) — Registration statement into which information is incorporated
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to furnish the Securities and Exchange Commission with an Amended and Restated Material Change Report dated July 4, 2024, and a related press release, incorporating them by reference into the company's F-3 registration statement.
When was the Amended and Restated Material Change Report dated?
The Amended and Restated Material Change Report was dated July 4, 2024.
What exhibits are included with this Form 6-K?
This Form 6-K includes Exhibit 99.1 (the Amended and Restated Material Change Report) and Exhibit 99.2 (the press release relating to the Amended Report).
Into which registration statement is the information incorporated?
The information is incorporated by reference into the Registrant's Registration Statement on Form F-3.
What is FSD Pharma Inc.'s principal executive office address?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Filing Stats: 252 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-07-08 15:20:52
Filing Documents
- fsd_6k.htm (6-K) — 12KB
- fsd_ex991.htm (EX-99.1) — 35KB
- fsd_ex992.htm (EX-99.2) — 24KB
- 0001654954-24-008703.txt ( ) — 72KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: July 8, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Number Description of Exhibit 99.1 Amended and Restated Material Change Report, dated July 4, 2024 99.2 Press Release, dated July 4, 2024 4